View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Aug. 01, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	ReWalk Robotics Ltd.
Entity Central Index Key	0001607962
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		12,482,160
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 15,686	$ 17,869
Trade receivable, net of allowance for doubtful accounts of $186 and $144 as of June 30, 2016 and December 31, 2015, respectively	1,187	2,146
Prepaid expenses and other current assets	1,792	1,227
Inventory	3,415	2,534
Total current assets	22,080	23,776
LONG-TERM ASSETS
Other long term assets	1,107	470
Property and equipment, net	1,451	1,328
Total long-term assets	2,558	1,798
Total assets	24,638	25,574
CURRENT LIABILITIES:
Current maturities of long term loan	3,963	0
Trade payables	4,239	2,474
Employees and payroll accruals	869	1,221
Deferred revenues and customers advances	253	199
Other current liabilities	511	449
Total current liabilities	9,835	4,343
LONG-TERM LIABILITIES
Long term loan, net of current maturities	6,344	0
Deferred revenues	225	171
Other long-term liabilities	184	140
Total long-term liabilities	6,753	311
Total liabilities	16,588	4,654
COMMITMENTS AND CONTINGENT LIABILITIES
Share capital
Ordinary shares, par value NIS 0.01 per share-Authorized: 250,000,000 shares at June 30, 2016 and December 31, 2015; Issued and outstanding: 12,481,978 and 12,222,583 shares at June 30, 2016 and December 31, 2015, respectively	33	33
Additional paid-in capital	98,045	94,876
Accumulated deficit	(90,028)	(73,989)
Total shareholders’ equity	8,050	20,920
Total liabilities and shareholders’ equity	$ 24,638	$ 25,574

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) $ in Thousands	Jun. 30, 2016 USD ($) shares	Jun. 30, 2016 ₪ / shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2015 ₪ / shares
Statement of Financial Position [Abstract]
Trade receivable, allowance for doubtful accounts \| $	$ 186		$ 144
Ordinary shares, par value (in ILS per share) \| ₪ / shares		₪ 0.01		₪ 0.01
Ordinary shares, shares authorized (in shares)	250,000,000		250,000,000
Ordinary shares, shares Issued (in shares)	12,481,978		12,222,583
Ordinary shares, shares outstanding (in shares)	12,481,978		12,222,583

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Revenues	$ 817	$ 610	$ 2,878	$ 1,245
Cost of revenues	732	550	2,300	1,152
Gross profit	85	60	578	93
Operating expenses:
Research and development	3,074	1,450	4,769	2,987
Sales and marketing	3,504	2,996	6,803	5,514
General and administrative	2,095	1,457	4,009	2,956
Total operating expenses	8,673	5,903	15,581	11,457
Operating loss	(8,588)	(5,843)	(15,003)	(11,364)
Financial income (expenses), net	(517)	50	(1,006)	(119)
Loss before income taxes	(9,105)	(5,793)	(16,009)	(11,483)
Income taxes	12	15	30	31
Net loss	$ (9,117)	$ (5,808)	$ (16,039)	$ (11,514)
Net loss per ordinary share, basic and diluted (in USD per share)	$ (0.74)	$ (0.48)	$ (1.30)	$ (0.95)
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted (in shares)	12,403,541	12,125,563	12,363,698	12,066,945

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands

Total

Ordinary Share

Additional paid-in capital

Accumulated deficit

Balance at Dec. 31, 2014

$ 43,853

$ 32

$ 92,395

$ (48,574)

Balance (in shares) at Dec. 31, 2014

11,978,554

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation to employees and non-employees

2,345

Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non employees

137

$ 1

136

Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employee and non employees (in shares)

194,345

Cashless exercise of warrants into ordinary shares (in shares)

49,684

Net loss

(25,415)

Balance at Dec. 31, 2015

20,920

$ 33

94,876

(73,989)

Balance (in shares) at Dec. 31, 2015

12,222,583

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation to employees and non-employees

1,543

Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $333

^[1]

437

Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $333 (in shares)

^[1]

100,075

Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non employees

$ 28

Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employee and non employees (in shares)

114,204

Cashless exercise of warrants into ordinary shares (in shares)

45,116

Issuance of warrants to purchase ordinary shares

^[2]

$ 1,161

1,161

Net loss

(16,039)

Balance at Jun. 30, 2016

$ 8,050

$ 33

$ 98,045

$ (90,028)

Balance (in shares) at Jun. 30, 2016

12,481,978

[1]	See Note 8e to the condensed consolidated financial statements.
[2]	See note 6 to the condensed consolidated financial statements

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) $ in Thousands	6 Months Ended
	Jun. 30, 2016 USD ($)
Ordinary Share
Issuance costs	$ 333

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands

6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Cash flows from operating activities:

Net loss

$ (16,039)

$ (11,514)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation

327

124

Share-based compensation to employees and non- employees

1,543

1,171

Deferred taxes

(59)

(27)

Financial expenses related to long term loan

322

Changes in assets and liabilities:

Trade receivables, net

959

438

Prepaid expenses and other current assets

(1,003)

(813)

Inventories

(936)

(3,105)

Trade payables

1,511

2,055

Employees and payroll accruals

(352)

356

Deferred revenues and advances from customers

108

Other liabilities

106

(781)

Net cash used in operating activities

(13,513)

(12,039)

Cash flows from investing activities:

Maturities of short-term deposits

1,667

Purchase of property and equipment

(395)

(351)

Net cash provided by (used in) investing activities

(395)

1,316

Cash flows from financing activities:

Issuance of ordinary shares upon exercise of options to purchase ordinary shares by employees and non employees

Proceeds from long term loan

12,000

Debt issuance cost

(441)

Proceeds from long term loan

(553)

Issuance of ordinary shares in at-the-market offering, net of issuance expenses paid in the amount of $79

^[1]

691

Net cash provided by financing activities

11,725

Decrease in cash and cash equivalents

(2,183)

(10,657)

Cash and cash equivalents at beginning of period

17,869

41,829

Cash and cash equivalents at end of period

15,686

31,172

Supplemental disclosures of non-cash flow information

At-the-market offering expenses not yet paid

254

Classification of inventory to property and equipment, net

$ 55

$ 360

[1]	See Note 8e to the condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	6 Months Ended
	Jun. 30, 2016 USD ($)
Statement of Cash Flows [Abstract]
Issuance expenses	$ 79

GENERAL

6 Months Ended

Jun. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GENERAL


a.	ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date.


b.	RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc., incorporated under the laws of Delaware on February 15, 2012, and (ii) Argo Medical Technologies GmbH, incorporated under the laws of Germany on January 14, 2013.


c.	The Company depends on one contract manufacturer. Reliance on this vendor makes the Company vulnerable to possible capacity constraints and reduced control over component availability, delivery schedules, manufacturing yields and costs. This vendor accounted for 20% and 24% of the Company's total trade payables as of June 30, 2016 and December 31, 2015, respectively.


d.	On May 16, 2016 the Company has entered into a Research Collaboration Agreement and an Exclusive License Agreement with the President and Fellows of Harvard College ("Harvard"). See also Note 7 below for more information about these agreements with Harvard.

During May and June 2016, the Company issued and sold 100,075 ordinary shares at an average price of $7.69 per share under its ATM Offering Program. The gross proceeds to the Company were $770 thousand, and the net proceeds after deducting commissions, fees and offering expenses in the amount of $333 thousand were $437 thousand. The Company can raise up to $25 million under its ATM Offering Program. See Note 8e below for more information about the Company’s ATM Offering Program.

The Company has incurred losses in the amount of $16 million during the six month period ended June 30, 2016. The Company has an accumulated deficit in the total amount of $90 million as of June 30, 2016 and negative cash flow from operating activities is in the amount of $13.5 million for the six-month period ended June 30, 2016. As of June 30, 2016, the Company had cash and cash equivalents of $15.7 million. The Company expects to fund future capital requirements from its cash and cash equivalents, cash flow generated from its operations, borrowings under the Loan Agreement with Kreos Capital V (Expert Fund) Limited, issuances under the Company's ATM Offering Program or, other future issuances of equity and debt securities, or through a combination of the foregoing to meet the Company's anticipated cash requirements for the next 12 months. See Note 6 below for information about the Company’s Loan Agreement.

UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Notes)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company's (i)consolidated financial position as of June 30, 2016, (ii) consolidated results of operations for the three and six months ended June 30, 2016 and (iii) consolidated cash flows for the six month ended June 30, 2016. The results for the three and six month periods ended June 30, 2016, as applicable, are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies applied in the audited consolidated financial statements of the Company as disclosed in the Company's annual report on Form 10-K for the year ended December 31, 2015 filed with the SEC on February 29, 2016, as amended on Form 10-K/A filed with the SEC on May 5, 2016 (the “2015 Form 10-K”), are applied consistently in these unaudited interim condensed consolidated financial statements.


b.	New Accounting Pronouncements:

In March 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2016-09, Compensation-Stock Compensation (Topic 718). The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this standard are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact of the pending adoption of this ASU on its condensed consolidated financial statements and related disclosures.

ii.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Under the new guidance, a lessee will be required to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current generally accepted accounting principles, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. This ASU requires additional disclosures. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within those fiscal years. The ASU requires adoption based upon a modified retrospective transition approach. Early adoption is permitted. The Company has not yet selected a transition method or determined whether it will elect early adoption and is currently evaluating the impact of the pending adoption of this ASU on its condensed consolidated financial statements and related disclosures.

iii.

In 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. In 2016, the FASB issued four amendments to ASU 2014-09. The standard is effective for public companies for annual and interim periods beginning after December 15, 2017. Early adoption is permitted as of one year prior to the current effective date. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The Company has not yet selected an implementation approach or determined whether it will elect early adoption and is currently evaluating the impact of the pending adoption of this ASU on its condensed consolidated financial statements and related disclosures.


c.	Concentrations of Credit Risks:

Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. One customer represented 10% and 21% of the Company's trade receivable, net balance as of June 30, 2016 and December 31, 2015, respectively.

INVENTORY

6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

INVENTORY

The components of inventory are as follows (in thousands):



	June 30,		December 31,
	2016		2015
Raw materials	$	975	$	450
Finished products	2,440		2,084
	$	3,415	$	2,534

COMMITMENTS AND CONTINGENT LIABILITIES

6 Months Ended

Jun. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES


a.	Purchase commitments:

The Company has contractual obligations to purchase goods from its contract manufacturer- Sanmina Corporation, as further discussed in "Part I Item 1. Business" and "Part I, Item 1A. Risk Factors" of the 2015 Form 10-K. Purchase obligations do not include contracts that may be canceled without penalty. As of June 30, 2016, non-cancelable outstanding obligations amounted to approximately $2.7 million.


b.	Liens:

As described in Note 6 below, in connection with the loan agreement, dated as of December 30, 2015, between Kreos Capital V (Expert) Fund Limited (Kreos) and the Company (the Loan Agreement), the Company granted Kreos a first priority security interest over all of its assets, including intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests.

The Company's other long-term assets subject to liens include a bank deposit in the amount of $746 thousand, which was pledged as security in respect of guaranties made in favor of a third party on April 29, 2015 and on January 6, 2016. Such deposit cannot be pledged to others or withdrawn without the consent of such third party.

LOAN AND WARRANT TO PURCHASE ORDINARY SHARES LOAN AND WARRANT TO PURCHASE ORDINARY SHARES

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

LOANS AND WARRANT TO PURCHASE ORDINARY SHARES

LOAN AND WARRANT TO PURCHASE ORDINARY SHARES

On December 30, 2015, the Company entered into the Loan Agreement pursuant to which Kreos extended a line of credit to the Company in the amount of $20.0 million (the “Loan”). Pursuant to the Loan Agreement, the Company granted Kreos a first priority security interest over all of its assets, including intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests.

The Loan has a maturity of 36 months and bears annual interest of 10.75%, which is to be paid monthly. The principal of the Loan is to be paid in 24 monthly payments, beginning in January 2017, except for the last loan payment, which was paid in advance on the Draw Down Date (as defined below). The repayment period will be extended to 36 months if the Company raises $20.0 million or more in connection with the issuance of shares of its capital stock (including debt securities convertible into shares of the Company’s capital stock) prior to the expiration of the initial 24-month period. In the event that prior to December 31, 2016, the Company raises $10.0 million or more in connection with the issuance of shares of the Company’s capital stock (including debt securities convertible into shares of the Company’s capital stock), the Company will be able to draw down up to an additional $8.0 million in separate tranches until December 31, 2016, with a minimum required drawdown of $2.0 million each.

On January 4, 2016 (the “Draw Down Date”), the Company drew down $12.0 million, net of $415 thousand in loan transaction fees and $660 thousand as advance payment. Additional loan transaction fees in the amount of $26 thousand were paid after the Draw Down Date. Out of the $441 thousand in total loan transaction fees, $140 thousand are deferred, and presented within “Other long term assets”, as they are allocated to the remaining $8.0 million available for drawdown by the Company under the Loan Agreement in separate tranches until December 31, 2016, (assuming proceeds of at least $10.0 million prior to December 31, 2016 in connection with the issuance of shares of the Company's capital stock).

Repayment of the Loan and payment of all other amounts owed to Kreos are to be made in U.S. dollars.

The Company recorded interest expense in the amount of $967 thousand during the six months ended June 30, 2016.

In connection with the Loan Agreement, on December 30, 2015, the Company also granted Kreos a warrant to purchase 119,295 ordinary shares of the Company at an exercise price of $9.64 per share (the “Warrant”). The Warrant is exercisable, in whole or in part, at any time prior to the earliest of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly-owned subsidiary of the Company, excluding any transaction in which shareholders of the Company prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction.

On December 30, 2015, the Company calculated the value of its freestanding Warrant to purchase its ordinary shares in the amount of $1 million (net of $42 thousand issuance expenses), by using the relative fair value method and utilizing an option pricing method. The Company has recorded the value of the Warrant, together with the Loan's issuance costs, as debt discount which is being accreted as interest expense using the effective-interest method over the remaining term of the Loan.

The following assumptions were used to estimate the value of the Warrant on December 30, 2015:



	December 30, 2015
Expected volatility	60	%
Risk-free rate	2.52	%
Dividend yield	—	%
Expected term (in years)	10

RESEARCH COLLABORATION AND LICENSE AGREEMENT	6 Months Ended
RESEARCH COLLABORATION AND LICENSE AGREEMENT	Jun. 30, 2016
Research and Development [Abstract]
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT On May 16, 2016, the Company entered into a Research Collaboration Agreement (“Collaboration Agreement”) and an Exclusive License Agreement (“License Agreement”) with Harvard. Under the Collaboration Agreement, Harvard and the Company have agreed to collaborate on research regarding the development of lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, which are intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. The Company has committed to pay in quarterly installments for the funding of this research, subject to a minimum funding commitment under applicable circumstances. The Collaboration Agreement will expire on May 16, 2021. Under the License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration. The License Agreement requires the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents. As of June 30, 2016, the Company did not achieve any of these milestones, and given the early stage of the License Agreement, the Company cannot anticipate the likelihood that the milestones will be achieved. Moreover, since such royalties are dependent on future product sales which are neither determinable nor reasonably estimable, these royalty payments are not recorded on our consolidated condensed balance sheet as of June 30, 2016. The Company's total payment obligation under the Collaboration Agreement and of the License Agreement is $6.3 million, some of it is subject to a minimum funding commitment under applicable circumstances as indicated above. see “Part I. Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations-Obligations and Commercial Commitments”. The Company has recorded cost in the amount of $1.1 million, which is part of the total payment obligation indicated above, as research and development expenses related to the License Agreement and to the Collaboration Agreement for the three and six months ended June 30, 2016. For further discussion of the terms of the Collaboration Agreement and the License Agreement, see “Part I. Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations-Overview-Collaboration Agreement and License Agreement with Harvard”.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

SHAREHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

SHAREHOLDERS' EQUITY

SHAREHOLDERS’ EQUITY


a.	Share option plans:

As of June 30, 2016, and December 31, 2015, the Company had reserved 393,903 and 420,469 ordinary shares, respectively, for issuance to the Company’s and its affiliates’ respective employees, directors, officers and consultants under the Company's 2014 Incentive Compensation Plan (the “2014 Plan”).

Options to purchase ordinary shares generally vest over four years, with certain options granted to non-employee directors during the six months ended June 30, 2016, vesting over one year. Any option that is forfeited or canceled before expiration becomes available for future grants under the 2014 Plan.

The fair value for options granted during the six months ended June 30, 2016 and June 30, 2015 was estimated at the date of the grant using a Black-Scholes-Merton option pricing model with the following assumptions:



	Six Months Ended June 30,
	2016	2015
Expected volatility	53%-60%	60%
Risk-free rate	1.28%-1.60%	1.60%-1.77%
Dividend yield	—%	—%
Expected term (in years)	5.31-6.11	6.11
Share price	$8.48 - $11.88	$19.61- $20.97

The fair value of restricted stock units (RSUs) granted is determined based on the price of the Company's ordinary shares on the date of grant.

A summary of employee options to purchase ordinary shares and RSUs during the six months ended June 30, 2016 is as follows:



	Six Months Ended June 30, 2016
	Number		Average exercise price		Average remaining contractual life (in years) (1)	Aggregate intrinsic value (in thousands)
Options and RSUs outstanding at the beginning of the period	1,853,369		$	6.12	8.37	$	17,048
Options granted	381,835		9.32
RSUs granted	172,528		—
Options exercised (2)	(101,543	)	1.28
RSUs vested (2)	(21,571	)	—
RSUs forfeited	(228	)	—
Options forfeited	(22,084	)	10.20

Options and RSUs outstanding at the end of the period	2,262,306		$	6.42	8.30	$	5,558

Options and RSUs vested and expected to vest	2,209,859		$	6.42	8.28	$	5,444

Options exercisable at the end of the period	704,032		$	4.11	6.79	$	1,669


(1)	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.


(2)	During the six month period ended June 30, 2016, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested and options that were exercised on a net basis was 114,204 ordinary shares.

The weighted average grant date fair value of options granted during the six month periods ended June 30, 2016, and June 30, 2015 was $4.79, and $11.19, respectively. The weighted average grant date fair value of RSUs granted during the six month period ended June 30, 2016 and June 30, 2015 was $9.36 and $20.97, respectively.

The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders that hold options with positive intrinsic value exercised their options on the last date of the exercise period. Total intrinsic value of options exercised for each of the six month periods ended June 30, 2016 and June 30, 2015 was $830 thousand and $1.8 million, respectively. As of June 30, 2016, there were $9.6 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Company's 2012 Equity Incentive Plan and its 2014 Plan. This cost is expected to be recognized over a period of approximately 2.9 years.

The number of options and RSUs outstanding as of June 30, 2016 is set forth below, with options separated by range of exercise price.



Range of exercise price	Options and RSUs outstanding as of June 30, 2016	Weighted average remaining contractual life (years) (1)	Options exercisable as of June 30, 2016	Weighted average remaining contractual life (years) (1)
RSUs only	238,990	—	—	—
$0.82	34,377	4.54	34,377	4.54
$1.32	343,390	5.95	332,811	5.92
$1.48	406,832	7.53	230,772	7.53
$7.30- $8.99	755,211	9.42	6,965	9.34
$9.22- $10.98	223,056	9.86	—	0
$19.62-$20.97	260,450	8.48	99,107	8.48
	2,262,306	8.30	704,032	6.79


(1)	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.



	b.	Share-based awards to non-employee consultants:

The Company granted options to a non-employee consultant (the "Advisor") on March 12, 2007. As of June 30, 2016, the outstanding options granted to such Advisor were as follows:



Issuance date	Options for shares of ordinary share	Exercise price per share	Options exercisable	Exercisable through
	(number)		(number)
March 12, 2007	3,454	$—	3,454	March 12, 2017

On May 28, 2016, the Company entered into an agreement (the “Consulting Agreement”) with a separate non-employee consultant (the “Consultant”), under which the Consultant agreed to assist the Company in commercially promoting and expanding insurance coverage of the Company’s ReWalk devices. Compensation under the Consulting Agreement is due and payable only if the Consultant is successful, and will consist of agreed amounts in cash or ordinary shares and a percentage of certain sales resulting from the Consultant’s efforts. Additionally, the Company has agreed to pay the Consultant 10 percent of the increase in the Company’s market capitalization following the dates when coverage becomes active under national insurance policies that the Consultant secures for the Company. The increase in the Company’s market capitalization will be determined based on the increase between the average closing price over the ten days before disclosure of a relevant coverage decision and the average closing price over the ten days commencing 80 days after such disclosure. These variable payments, which will be made only for the first five national insurance policies the Consultant attains for the Company, (1) may be made in cash or stock at the Company’s choice and (2) may not exceed (i) $6 million for the date that the first national coverage policy takes effect, (ii) $5 million for the date that the second national coverage policy takes effect and (iii) $2 million for each of the dates that the next three national coverage policies take effect. The Company may need to seek shareholder approval pursuant to the rules of The NASDAQ Stock Market LLC should the Company elect to make such payments in stock. The Consulting Agreement has a term of 12 months, which will extend to 18 months if the Consultant secures a national coverage policy with certain insurers in the first 12 months and to 24 months if the Consultant secures at least two more national coverage policies within the first 18 months. Due to the fact that the compensation under the Consulting Agreement is based on achievement, the Company had not made any cash payments or issued any ordinary shares to the Consultant under the Consulting Agreement as of June 30, 2016.



	c.	Warrants to purchase ordinary shares:

During the six-months ended June 30, 2016, a total of 138,702 warrants were exercised on a cashless basis into 45,116 ordinary shares.

The following table summarizes information about warrants outstanding and exercisable as of June 30, 2016:



Issuance date	Warrants outstanding	Exercise price per warrant		Warrants exercisable	Contractual term
	(number)			(number)

July 14, 2014	403,804	$	10.08	403,804	July 13, 2018
December 30, 2015	119,295	$	9.64	119,295	Until the earlier of (i) December 30, 2025 or (ii) a merger, consolidation, or reorganization of the Company.
	523,099			523,099



	d.	Share-based compensation expense for employees and non-employees:

The Company recognized non-cash share-based compensation expense for both employees and non-employees

in the consolidated statements of operations for the periods shown below as follows (in thousands):



	Six Months Ended June 30,
	2016		2015
Cost of revenues	$	48	$	32
Research and development, net	249		201
Sales and marketing, net	376		265
General and administrative	870		673
Total	$	1,543	$	1,171

e. At-the-market offering program:

On May 10, 2016, the Company entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Jaffray, pursuant to which it may offer and sell, from time to time, ordinary shares having an aggregate offering price of up to $25 million, through Piper Jaffray acting as its agent. Subject to the terms and conditions of the Equity Distribution Agreement, Piper Jaffray will use its commercially reasonable efforts to sell on the Company’s behalf all of the ordinary shares requested to be sold by the Company, consistent with its normal trading and sales practices. Piper Jaffray may also act as principal in the sale of ordinary shares under the Equity Distribution Agreement. Sales may be made under the Company's registration statement on Form S-3, which was declared effective on May 9, 2016 (the “Form S-3”), in what may be deemed “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “ATM Offering Program”). Sales may be made directly on or through the NASDAQ Global Market, the existing trading market for the Company's ordinary shares, to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law, including in privately negotiated transactions. Piper Jaffray is entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold through it as agent under the Equity Distribution Agreement. Where Piper Jaffray acts as principal in the sale of ordinary shares under the Equity Distribution Agreement, such rate of compensation will not apply, but in no event will the total compensation of Piper Jaffray, when combined with the reimbursement of Piper Jaffray for the out-of-pocket fees and disbursements of its legal counsel, exceed 8.0% of the gross proceeds received from the sale of the ordinary shares. The Company is not required to sell any of its ordinary shares at any time.

As of August 2, 2016, the Company had sold 100,075 ordinary shares under the ATM Offering Program for net proceeds to the Company of $437 thousand (after commissions, fees and expenses). Additionally, as of that date, the Company had paid Piper Jaffray compensation of $23 thousand and had incurred total expenses of approximately $333 thousand in connection with the ATM Offering Program.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

FINANCIAL EXPENSES, NET

6 Months Ended

Jun. 30, 2016

Other Income and Expenses [Abstract]

FINANCIAL EXPENSES, NET

The components of financial expenses, net were as follows (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Foreign currency transactions and other	$	24		$	(55	)	$	43		$	106
Financial expenses related to loan agreement with Kreos	488			—			967			—
Bank commissions	14			13			23			21
Income related to hedging transactions	(9		)	(8		)	(27		)	(8		)
	$	517		$	(50	)	$	1,006		$	119

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA

Summary information about geographic areas:

ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing the enterprise’s performance. The Company manages its business on the basis of one reportable segment, and derives revenues from selling systems and services (see Note 1 above and “Part I, Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this quarterly report for a brief description of the Company’s business). The following is a summary of revenues within geographic areas (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Revenues based on customer’s location :
Israel	$	—	$	—	$	—	$	—
United States	527		376		2,266		950
Europe	244		162		504		219
Asia-Pacific	46		72		108		76
Total revenues	$	817	$	610	$	2,878	$	1,245



	June 30,		December 31,
	2016		2015
Long-lived assets by geographic region (*):
Israel	$	557	$	605
United States	693		483
Germany	201		240
	$	1,451	$	1,328

(*) Long-lived assets are comprised of property and equipment, net.

Major customer data as a percentage of total revenues (in thousands):



	June 30,	December 31,
	2016	2015
Customer A	*)	15	%

*) Less than 10%

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Basis of Accounting

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company's (i)consolidated financial position as of June 30, 2016, (ii) consolidated results of operations for the three and six months ended June 30, 2016 and (iii) consolidated cash flows for the six month ended June 30, 2016. The results for the three and six month periods ended June 30, 2016, as applicable, are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

New Accounting Pronouncements

New Accounting Pronouncements:

ii.

iii.

Concentrations of Credit Risks

Concentrations of Credit Risks:

INVENTORY (Tables)

6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

Schedule of inventories

The components of inventory are as follows (in thousands):



	June 30,		December 31,
	2016		2015
Raw materials	$	975	$	450
Finished products	2,440		2,084
	$	3,415	$	2,534

LOAN AND WARRANT TO PURCHASE ORDINARY SHARES (Tables)

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Schedule of assumptions used to estimate the value of the warrants

The following assumptions were used to estimate the value of the Warrant on December 30, 2015:



	December 30, 2015
Expected volatility	60	%
Risk-free rate	2.52	%
Dividend yield	—	%
Expected term (in years)	10

SHAREHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of stock option valuation assumptions



	Six Months Ended June 30,
	2016	2015
Expected volatility	53%-60%	60%
Risk-free rate	1.28%-1.60%	1.60%-1.77%
Dividend yield	—%	—%
Expected term (in years)	5.31-6.11	6.11
Share price	$8.48 - $11.88	$19.61- $20.97

Summary of stock option and RSU activity

A summary of employee options to purchase ordinary shares and RSUs during the six months ended June 30, 2016 is as follows:



	Six Months Ended June 30, 2016
	Number		Average exercise price		Average remaining contractual life (in years) (1)	Aggregate intrinsic value (in thousands)
Options and RSUs outstanding at the beginning of the period	1,853,369		$	6.12	8.37	$	17,048
Options granted	381,835		9.32
RSUs granted	172,528		—
Options exercised (2)	(101,543	)	1.28
RSUs vested (2)	(21,571	)	—
RSUs forfeited	(228	)	—
Options forfeited	(22,084	)	10.20

Options and RSUs outstanding at the end of the period	2,262,306		$	6.42	8.30	$	5,558

Options and RSUs vested and expected to vest	2,209,859		$	6.42	8.28	$	5,444

Options exercisable at the end of the period	704,032		$	4.11	6.79	$	1,669


(1)	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.


(2)	During the six month period ended June 30, 2016, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested and options that were exercised on a net basis was 114,204 ordinary shares.

Schedule of options and RSUs outstanding which have been separated into ranges of exercise price

The number of options and RSUs outstanding as of June 30, 2016 is set forth below, with options separated by range of exercise price.



Range of exercise price	Options and RSUs outstanding as of June 30, 2016	Weighted average remaining contractual life (years) (1)	Options exercisable as of June 30, 2016	Weighted average remaining contractual life (years) (1)
RSUs only	238,990	—	—	—
$0.82	34,377	4.54	34,377	4.54
$1.32	343,390	5.95	332,811	5.92
$1.48	406,832	7.53	230,772	7.53
$7.30- $8.99	755,211	9.42	6,965	9.34
$9.22- $10.98	223,056	9.86	—	0
$19.62-$20.97	260,450	8.48	99,107	8.48
	2,262,306	8.30	704,032	6.79


(1)	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

Schedule of outstanding options granted to non-employees

The Company granted options to a non-employee consultant (the "Advisor") on March 12, 2007. As of June 30, 2016, the outstanding options granted to such Advisor were as follows:



Issuance date	Options for shares of ordinary share	Exercise price per share	Options exercisable	Exercisable through
	(number)		(number)
March 12, 2007	3,454	$—	3,454	March 12, 2017

Schedule of warrants outstanding and exercisable

The following table summarizes information about warrants outstanding and exercisable as of June 30, 2016:



Issuance date	Warrants outstanding	Exercise price per warrant		Warrants exercisable	Contractual term
	(number)			(number)

July 14, 2014	403,804	$	10.08	403,804	July 13, 2018
December 30, 2015	119,295	$	9.64	119,295	Until the earlier of (i) December 30, 2025 or (ii) a merger, consolidation, or reorganization of the Company.
	523,099			523,099

Schedule of non-cash share-based compensation expense

The Company recognized non-cash share-based compensation expense for both employees and non-employees

in the consolidated statements of operations for the periods shown below as follows (in thousands):



	Six Months Ended June 30,
	2016		2015
Cost of revenues	$	48	$	32
Research and development, net	249		201
Sales and marketing, net	376		265
General and administrative	870		673
Total	$	1,543	$	1,171

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

FINANCIAL EXPENSES, NET (Tables)

6 Months Ended

Jun. 30, 2016

Other Income and Expenses [Abstract]

Schedule of financial expenses (income), net

The components of financial expenses, net were as follows (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Foreign currency transactions and other	$	24		$	(55	)	$	43		$	106
Financial expenses related to loan agreement with Kreos	488			—			967			—
Bank commissions	14			13			23			21
Income related to hedging transactions	(9		)	(8		)	(27		)	(8		)
	$	517		$	(50	)	$	1,006		$	119

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables)

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Schedule of revenues within geographic areas

The following is a summary of revenues within geographic areas (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Revenues based on customer’s location :
Israel	$	—	$	—	$	—	$	—
United States	527		376		2,266		950
Europe	244		162		504		219
Asia-Pacific	46		72		108		76
Total revenues	$	817	$	610	$	2,878	$	1,245

Schedule of long-lived assets by geographic region



	June 30,		December 31,
	2016		2015
Long-lived assets by geographic region (*):
Israel	$	557	$	605
United States	693		483
Germany	201		240
	$	1,451	$	1,328

(*) Long-lived assets are comprised of property and equipment, net.

Schedule of major customer data as a percentage of total revenues

Major customer data as a percentage of total revenues (in thousands):



	June 30,	December 31,
	2016	2015
Customer A	*)	15	%

*) Less than 10%

GENERAL (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
GENERAL (Details) $ in Thousands	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) subsidiary	Jun. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of wholly-owned subsidiaries \| subsidiary			2
Net loss	$ 9,117	$ 5,808	$ 16,039	$ 11,514	$ 25,415
Accumulated deficit	90,028		90,028		73,989
Cash flow from operating activity			13,513	12,039
Cash and cash equivalents	$ 15,686	$ 31,172	$ 15,686	$ 31,172	$ 17,869	$ 41,829

GENERAL - Concentration Risk (Details) - Vendor concentration - Trade payables - manufacturer	Jun. 30, 2016	Dec. 31, 2015
Concentration Risk [Line Items]
Number of contract manufacturers	1	1
Concentration risk (as a percent)	20.00%	24.00%

GENERAL - ATM Offering Program (Details) - USD ($)

2 Months Ended

6 Months Ended

Jun. 30, 2016

May 10, 2016

Class of Stock [Line Items]

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses

^[1]

$ 437,000

Maximum amount which can be raised under ATM offering program

$ 25,000,000

$ 25,000,000.0

ATM Offering Program

Class of Stock [Line Items]

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses (in shares)

100,075

Gross proceeds from shares issued under the ATM offering program

$ 770,000

Underwriter commission and offering expenses

333,000

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses

$ 437,000

ATM Offering Program | Weighted Average

Class of Stock [Line Items]

Price per share of shares sold under ATM offering program (in USD per share)

$ 7.69

[1]	See Note 8e to the condensed consolidated financial statements.

SIGNIFICANT ACCOUNTING POLICIES (Concentrations of Credit Risks) (Details) - Trade Receivable - Customer concentration - customer	Jun. 30, 2016	Dec. 31, 2015
Concentration Risk [Line Items]
Number of customers	1	1
Concentration risk (as a percent)	10.00%	21.00%

INVENTORY (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 975	$ 450
Finished products	2,440	2,084
Inventories	$ 3,415	$ 2,534

COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2016 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Outstanding purchase orders	$ 2,700
Collateral pledged	$ 746

LOAN AND WARRANT TO PURCHASE ORDINARY SHARES Term Loan (Details) - USD ($)			3 Months Ended		6 Months Ended
	Jan. 04, 2016	Dec. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Number of monthly payments		24 months
Minimum amount required to be raised in order to drawn down remaining credit facility			$ 10,000,000		$ 10,000,000	$ 10,000,000	$ 10,000,000
Payment of loan transaction fee							441,000	$ 0
Financial expenses related to loan agreement with Kreos			488,000	$ 0			967,000	$ 0
Term Loan \| 10.75% Term Loan Due January 2019
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 20,000,000
Loan term		36 months
Annual interest rate (as a percent)		10.75%
Number of monthly payments		24 months
Minimum amount to be raised by issuance of capital stock for extended loan term		$ 20,000,000
Minimum amount required to be raised in order to drawn down remaining credit facility		10,000,000
Remaining borrowing capacity under loan agreement		8,000,000	8,000,000		8,000,000	8,000,000	8,000,000
Minimum draw down amount		$ 2,000,000
Loan proceeds	$ 12,000,000
Payment of loan transaction fee	415,000				441,000	26,000
Advance payment	$ 660,000
Deferred loan transaction fees			$ 140,000		$ 140,000	$ 140,000	140,000
Financial expenses related to loan agreement with Kreos							$ 967,000

LOAN AND WARRANT TO PURCHASE ORDINARY SHARES Warrants (Details)
$ / shares in Units, $ in Thousands

6 Months Ended

Dec. 30, 2015

USD ($)

$ / shares

Jun. 30, 2016

USD ($)

Class of Warrant or Right [Line Items]

Fair value of warrants

^[1]

$ 1,161

Ordinary Share

Class of Warrant or Right [Line Items]

Number of warrants issued (in shares) | shares

119,295

138,702

Exercise price (in USD per share) | $ / shares

$ 9.64

Minimum percentage in acquired company required to prevent warrants from becoming exercisable

0.5

Fair value of warrants

$ 1,000

Transaction fee expenses

$ 42

[1]	See note 6 to the condensed consolidated financial statements

LOAN AND WARRANT TO PURCHASE ORDINARY SHARES Warrants Fair Value Assumptions (Details) - Ordinary Share	Dec. 30, 2015
Class of Warrant or Right [Line Items]
Expected volatility (as a percent)	60.00%
Risk-free rate (as a percent)	2.52%
Dividend yield (as a percent)	0.00%
Expected term (in years)	10 years

RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development	$ 3,074	$ 1,450	$ 4,769	$ 2,987
Collaboration and Licensing Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total payment obligation	6,300		6,300
Research and development	$ 1,100		$ 1,100

SHAREHOLDERS' EQUITY (Narrative - Share Option Plans) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Shareholders' equity (deficiency) [Line Items]
Unrecognized compensation cost	$ 9,600
Period of recognition of unrecognized compensation cost	2 years 10 months 24 days
Options
Shareholders' equity (deficiency) [Line Items]
Shares reserved for future issuance (in shares)	393,903		420,469
Award vesting period	4 years
Weighted average grant date fair values, options (in USD per share)	$ 4.79	$ 11.19
Total intrinsic value of options exercised	$ 830	$ 1,800
RSU
Shareholders' equity (deficiency) [Line Items]
Weighted average grant date fair values, RSUs (in USD per share)	$ 9.36	$ 20.97
Non-employee Director \| Options
Shareholders' equity (deficiency) [Line Items]
Award vesting period	1 year

SHAREHOLDERS' EQUITY (Option Valuation Assumptions) (Details) - $ / shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum (as a percent)	53.00%
Expected volatility, maximum (as a percent)	60.00%
Expected volatility (as a percent)		60.00%
Risk-free rate, minimum (as a percent)	1.28%	1.60%
Risk-free rate, maximum (as a percent)	1.60%	1.77%
Dividend yield (as a percent)	0.00%	0.00%
Expected term (in years)		6 years 1 month 10 days
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years 3 months 22 days
Share price (in USD per share)	$ 8.48	$ 19.61
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 1 month 10 days
Share price (in USD per share)	$ 11.88	$ 20.97

SHAREHOLDERS' EQUITY (Summary of Employee Share Option and RSU Activity ) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Aggregate intrinsic value (in thousands)
Issuance of ordinary share upon exercise of stock options and vesting of RSUs (in shares)	114,204
Stock Options and RSUs
Number
Options and RSU's outstanding at the beginning of the period (in shares)	1,853,369
Options and RSU's outstanding at the end of the period (in shares)	2,262,306
Options and RSUs vested and expected to vest (in shares)	2,209,859
Average exercise price
Options and RSUs outstanding at the beginning of the period (in USD per share)	$ 6.12
Options and RSUs outstanding at the end of the period (in USD per share)	6.42
Options and RSUs vested and expected to vest (in USD per share)	$ 6.42
Average remaining contractual life (years)
Options and RSUs outstanding	8 years 3 months 18 days	8 years 4 months 13 days
Options and RSUs vested and expected to vest	8 years 3 months 11 days
Aggregate intrinsic value (in thousands)
Options and RSUs outstanding at beginning of the period	$ 17,048
Options and RSUs outstanding at the end of the period	5,558
Options and RSUs vested and expected to vest	$ 5,444
Options
Number
Options granted (in shares)	381,835
Options exercised (in shares)	(101,543)
Options forfeited (in shares)	(22,084)
Options exercisable at the end of the period (in shares)	704,032
Average exercise price
Options granted (in USD per share)	$ 9.32
Options exercised (in USD per share)	1.28
Options forfeited (in USD per share)	10.20
Options exercisable at the end of the period (in USD per share)	$ 4.11
Average remaining contractual life (years)
Options exercisable at the end of the period	6 years 9 months 15 days
Aggregate intrinsic value (in thousands)
Options exercisable at the end of the period	$ 1,669
RSU
Number
RSUs granted (in shares)	172,528
RSUs vested (in shares)	(21,571)
RSUs forfeited (in shares)	(228)

SHAREHOLDERS' EQUITY (Schedule of Options and RSUs Outstanding Which have been Separated into Ranges of Exercise Price) (Details) - $ / shares	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
RSU
Ranges of Exercise Price [Line Items]
RSUs outstanding (in shares)	238,990
Options
Ranges of Exercise Price [Line Items]
Options exercisable (in shares)	704,032
Options exercisable weighted average remaining contractual life (years)	6 years 9 months 15 days
Stock Options and RSUs
Ranges of Exercise Price [Line Items]
Options outstanding weighted average remaining contractual life (years)	8 years 3 months 18 days
Options and RSU's outstanding (in shares)	2,262,306	1,853,369
$0.82 \| Options
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in USD per share)	$ 0.82
Range of exercise price, maximum (in USD per share)	$ 0.82
Options outstanding (in shares)	34,377
Options outstanding weighted average remaining contractual life (years)	4 years 6 months 15 days
Options exercisable (in shares)	34,377
Options exercisable weighted average remaining contractual life (years)	4 years 6 months 15 days
$1.32 \| Options
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in USD per share)	$ 1.32
Range of exercise price, maximum (in USD per share)	$ 1.32
Options outstanding (in shares)	343,390
Options outstanding weighted average remaining contractual life (years)	5 years 11 months 12 days
Options exercisable (in shares)	332,811
Options exercisable weighted average remaining contractual life (years)	5 years 11 months 1 day
$1.48 \| Options
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in USD per share)	$ 1.48
Range of exercise price, maximum (in USD per share)	$ 1.48
Options outstanding (in shares)	406,832
Options outstanding weighted average remaining contractual life (years)	7 years 6 months 11 days
Options exercisable (in shares)	230,772
Options exercisable weighted average remaining contractual life (years)	7 years 6 months 11 days
$7.30- $8.99 \| Options
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in USD per share)	$ 7.30
Range of exercise price, maximum (in USD per share)	$ 8.99
Options outstanding (in shares)	755,211
Options outstanding weighted average remaining contractual life (years)	9 years 5 months 1 day
Options exercisable (in shares)	6,965
Options exercisable weighted average remaining contractual life (years)	9 years 4 months 2 days
$9.22- $10.98 \| Options
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in USD per share)	$ 9.22
Range of exercise price, maximum (in USD per share)	$ 10.98
Options outstanding (in shares)	223,056
Options outstanding weighted average remaining contractual life (years)	9 years 10 months 10 days
Options exercisable (in shares)	0
Options exercisable weighted average remaining contractual life (years)	0 days
$19.62-$20.97 \| Options
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in USD per share)	$ 19.62
Range of exercise price, maximum (in USD per share)	$ 20.97
Options outstanding (in shares)	260,450
Options outstanding weighted average remaining contractual life (years)	8 years 5 months 23 days
Options exercisable (in shares)	99,107
Options exercisable weighted average remaining contractual life (years)	8 years 5 months 23 days

SHAREHOLDERS' EQUITY (Schedule of Outstanding Options Granted to Non-employees) (Details) - Nonemployee Stock Option - March 12, 2007	Jun. 30, 2016 $ / shares shares
Shareholders' equity (deficiency) [Line Items]
Options for shares of ordinary share (in shares)	3,454
Exercise price per share (in USD per shares) \| $ / shares	$ 0
Options exercisable (in shares)	3,454

SHAREHOLDERS' EQUITY SHAREHOLDER'S EQUITY (Share-based Awards to Non-Employee Consultants) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2016 USD ($) national_insurance_policy	May 28, 2016
Share-based Goods and Nonemployee Services Transaction [Line Items]
Consultant fee as a percentage of the increase in market capitalization		10.00%
Measurement period of increase in market capitalization following achievement of milestone	10 days
Disclosure period following achievement of milestone	80 days
Number of national insurance policies required \| national_insurance_policy	5
Agreement term	12 months
One Active National Insurance Policy
Share-based Goods and Nonemployee Services Transaction [Line Items]
Payments due in cash or stock	$ 6
Agreement term	18 months
Number of national insurance policies required to increase term \| national_insurance_policy	2
Two Active National Insurance Policies
Share-based Goods and Nonemployee Services Transaction [Line Items]
Payments due in cash or stock	$ 5
Three Active National Insurance Policies
Share-based Goods and Nonemployee Services Transaction [Line Items]
Agreement term	24 months
Three, Four, or Five Active National Insurance Policies
Share-based Goods and Nonemployee Services Transaction [Line Items]
Payments due in cash or stock	$ 2

SHAREHOLDER'S EQUITY (Schedule of Warrants) (Details) - $ / shares	6 Months Ended
	Jun. 30, 2016	Dec. 30, 2015
Ordinary Share
Class of Warrant or Right [Line Items]
Warrants exercised into ordinary shares (in shares)	138,702	119,295
Ordinary shares issued upon exercise of warrants (in shares)	45,116
Warrants outstanding (in shares)	523,099
Exercise price (in USD per share)		$ 9.64
Warrants exercisable (in shares)	523,099
Warrants to Purchase Ordinary Shares Issued on July 14, 2014
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	403,804
Exercise price (in USD per share)	$ 10.08
Warrants exercisable (in shares)	403,804
Warrants to Purchase Ordinary Shares Issued on December 30, 2015
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	119,295
Exercise price (in USD per share)	$ 9.64
Warrants exercisable (in shares)	119,295

SHAREHOLDERS' EQUITY (Schedule of Non-cash Share-based Compensation Expense) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	$ 1,543	$ 1,171
Cost of revenues
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	48	32
Research and development, net
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	249	201
Sales and marketing, net
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	376	265
General and administrative
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	$ 870	$ 673

SHAREHOLDER'S EQUITY (Narrative- Share-based Compensation Expense for employees and non-employees) (Details) - USD ($)

2 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2016

Aug. 02, 2016

Jun. 30, 2016

May 10, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Maximum amount which can be raised under ATM offering program

$ 25,000,000

$ 25,000,000.0

Share-based Goods and Nonemployee Services Transaction [Line Items]

Stock issuance costs under equity distribution agreement as a percent of gross proceeds

3.00%

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses

^[1]

437,000

Issuance expenses

$ 79,000

ATM Offering Program

Share-based Goods and Nonemployee Services Transaction [Line Items]

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses (in shares)

100,075

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses

$ 437,000

Maximum

Share-based Goods and Nonemployee Services Transaction [Line Items]

Stock issuance costs under equity distribution agreement as a percent of gross proceeds

8.00%

Subsequent Event | ATM Offering Program

Share-based Goods and Nonemployee Services Transaction [Line Items]

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses (in shares)

100,075

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses

$ 437,000

Total expenses incurred under ATM program

333,000

Subsequent Event | Piper Jaffray | ATM Offering Program

Share-based Goods and Nonemployee Services Transaction [Line Items]

Issuance expenses

$ 23,000

[1]	See Note 8e to the condensed consolidated financial statements.

FINANCIAL EXPENSES, NET (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
FINANCIAL EXPENSES, NET (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Other Income and Expenses [Abstract]
Foreign currency transactions and other	$ 24	$ (55)	$ 43	$ 106
Financial expenses related to loan agreement with Kreos	488	0	967	0
Bank commissions	14	13	23	21
Income related to hedging transactions	(9)	(8)	(27)	(8)
Financial expenses (income), net	$ 517	$ (50)	$ 1,006	$ 119

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Additional Information (Details)	6 Months Ended
	Jun. 30, 2016 segment
Segment Reporting [Abstract]
Number of reportable segments	1

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Schedule of revenues and long-lived assets by geographic region) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	$ 817	$ 610	$ 2,878	$ 1,245
Long-lived assets	1,451		1,451		$ 1,328
Israel
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	0	0	0	0
Long-lived assets	557		557		605
United States
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	527	376	2,266	950
Long-lived assets	693		693		483
Europe
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	244	162	504	219
Asia-Pacific
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	46	$ 72	108	$ 76
Germany
Summary of revenues and long-lived assets by geographic region [Line items]
Long-lived assets	$ 201		$ 201		$ 240

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Schedule of major customer data as a percentage of total revenues) (Details)

6 Months Ended

12 Months Ended

Jun. 30, 2016

Dec. 31, 2015

Revenue | Customer concentration | Customer A

Major customer data as a percentage of total revenues [Line items]

Concentration risk (as a percent)

0.00%

^[1]

15.00%

[1]	*) Less than 10%